Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial.

ABSTRACT:

Importance

Current treatments manage symptoms of Parkinson disease (PD), but no known treatment slows disease progression. Preclinical and epidemiological studies support the potential use of statins as disease-modifying therapy.

Objective

To determine whether simvastatin has potential as a disease-modifying treatment for patients with moderate PD.

Design, setting, and participants

This randomized clinical trial, a double-blind, parallel-group, placebo-controlled futility trial, was conducted between March 2016 and May 2020 within 23 National Health Service Trusts in England. Participants aged 40 to 90 years with a diagnosis of idiopathic PD, with a modified Hoehn and Yahr stage of 3.0 or less while taking medication, and taking dopaminergic medication with wearing-of

SUBMITTER: Stevens KN 

PROVIDER: S-EPMC9623477 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature